KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $2.30 $2.95 Friday, 26th Apr 2024 CLLS stock ended at $2.51. This is 0.627% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 6.62% from a day low at $2.35 to a day high of $2.51.
90 days $2.30 $3.13
52 weeks $0.96 $3.77

Historical Cellectis S.A. prices

Date Open High Low Close Volume
Oct 29, 2021 $11.12 $11.15 $10.72 $10.76 62 482
Oct 28, 2021 $10.53 $11.06 $10.51 $10.98 96 511
Oct 27, 2021 $10.71 $10.83 $10.47 $10.62 90 907
Oct 26, 2021 $10.97 $11.22 $10.74 $10.78 92 486
Oct 25, 2021 $10.68 $11.09 $10.60 $10.86 131 800
Oct 22, 2021 $11.13 $11.13 $10.65 $10.77 88 983
Oct 21, 2021 $11.03 $11.46 $11.03 $11.23 144 701
Oct 20, 2021 $10.92 $11.00 $10.75 $10.94 95 466
Oct 19, 2021 $10.61 $11.25 $10.54 $10.82 264 306
Oct 18, 2021 $10.69 $11.06 $10.41 $10.50 166 420
Oct 15, 2021 $10.54 $10.87 $10.45 $10.83 241 044
Oct 14, 2021 $9.88 $10.84 $9.78 $10.70 585 563
Oct 13, 2021 $9.77 $9.89 $9.33 $9.62 468 487
Oct 12, 2021 $9.15 $9.35 $9.10 $9.15 266 652
Oct 11, 2021 $8.95 $9.21 $8.95 $9.03 334 045
Oct 08, 2021 $10.11 $10.11 $8.72 $9.11 2 180 252
Oct 07, 2021 $12.00 $12.16 $11.84 $12.02 276 102
Oct 06, 2021 $12.23 $12.43 $11.83 $11.97 160 199
Oct 05, 2021 $12.49 $12.89 $12.20 $12.48 104 350
Oct 04, 2021 $12.49 $12.55 $12.07 $12.17 232 230
Oct 01, 2021 $12.62 $12.70 $12.25 $12.69 121 627
Sep 30, 2021 $12.65 $13.12 $12.60 $12.61 141 840
Sep 29, 2021 $13.07 $13.24 $12.37 $12.63 152 457
Sep 28, 2021 $13.63 $13.63 $12.96 $12.96 109 828
Sep 27, 2021 $13.57 $13.74 $13.24 $13.51 98 177
Click to get the best stock tips daily for free!

About Cellectis S.A.

Cellectis S.A. Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL... CLLS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT